Pharmacological Aspects of Neonatal Antidepressant Withdrawal
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Depression is common in reproductive age women, and continued pharmacologic treatment of depression during pregnancy may be necessary to prevent relapse, which could be harmful for both the fetus and the mother. Although data on drug safety are imperfect and incomplete, the benefits of antidepressant therapy during pregnancy generally outweigh the risks. Neonates who are exposed to antidepressant medications during gestation are at increased risk to have neonatal withdrawal syndrome, although the exact incidence of this complication is unknown because the definition of the syndrome is not clear and withdrawal reactions are probably underreported. Tricyclic antidepressant withdrawal syndrome is most likely related to muscarinergic activity and individual drug half-lives, and selective serotonin reuptake inhibitor withdrawal may be due to a decrease in available synaptic serotonin in the face of down-regulated serotonin receptors, the secondary effects of other neurotransmitters, and biological or cognitive sensitivity. Other factors that influence neonatal toxicity or withdrawal include the normal physiologic changes of pregnancy, the altered activity of CYP450 enzymes during pregnancy, drug-drug transporter (PgP and OCT3) interaction, and the presence of genetic polymorphisms in genes influencing drug metabolism. Further research is necessary. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians Learning Objectives: After completion of this article, the reader should be able to explain the importance of antidepressant therapy during pregnancy and postpartum, summarize the important neonatal effects of antidepressants, and describe the potential teratogenic effects of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Depression During Pregnancy: Systematic Review
Bennett, H. A., Einarson, A., Taddio, A., Koren, G., & Einarson, T. R. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000116689.75396.5f · Cited by 1,725
Health Measurement Scales: A Practical Guide To Their Development And Use
Streiner, D. L., & Norman, G. R. (2003) · doi:10.1093/oso/9780198528470.001.0001 · Cited by 1,460
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Implications of Antenatal Depression and Anxiety for Obstetric Outcome
Andersson, L., Sundström-Poromaa, I., Wulff, M., Åström, M., & Bixo, M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000135277.04565.e9 · Cited by 362
Maternal Depressive Symptoms and the Risk of Poor Pregnancy Outcome
Orr, S. T., & Miller, C. A. (1995) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036172 · Cited by 281
Abdel-Latif, M. E., Pinner, J., Clews, S., Cooke, F., Lui, K., & Oei, J. (2006) · Pediatrics · doi:10.1542/peds.2005-1561 · Cited by 266
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 4×
“Although monitoring for 1 week after birth has been recommended (85), this is currently not part of standard neonatal care.”
BackgroundInfluentialLattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211352 · Cited by 189 · cited 8×
“Respiratory distress Fluoxetine (68,120,121,160) Clomipramine (93,159,162,163,167)”
InfluentialPharmacokinetics of caffeine during and after pregnancy
Brazier, J. L., Ritter, J., Berland, M., Khenfer, D., & Faucon, G. (2017) · Developmental Pharmacology and Therapeutics · doi:10.1159/000457332 · Cited by 155 · cited 1×
“Anderson reviewed CYP1A2 activity during pregnancy (59), and showed the activity of CYP1A2 is reduced about 65% to 70% at the end of pregnancy, compared with the postpartum period (59,71).”
BackgroundHistory and description of the Neonatal Intensive Care Unit Network Neurobehavioral Scale
Lester, B. M., & Tronick, E. Z. (2004) · PEDIATRICS · doi:10.1542/peds.113.s2.634 · Cited by 154 · cited 2×
“With no alternatives, the Committee on Drugs of the American Academy of Pediatrics has stated that neonatal withdrawal symptoms related to in utero exposure to clomipramine may be compared to symptoms associated with withdrawal from exposure to maternal narcotics ( 140 ).”
Background
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Deligiannidis, K. M., Byatt, N., & Freeman, M. P. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000087 · Cited by 186
The use of psychotropic medication during pregnancy: how about the newborn?
Kieviet, N., Honig, & Dolman (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36394 · Cited by 100
Convertino, I., Sansone, A. C., Marino, A., Galiulo, M. T., Mantarro, S., Antonioli, L., Fornai, M., Blandizzi, C., & Tuccori, M. (2016) · Drug Safety · doi:10.1007/s40264-016-0435-8 · Cited by 32
Metadata
- Authors
- ter Horst, P. G. J., Jansman, F. G. A., van Lingen, R. A., Smit, J.-P., de Jong-van den Berg, L. T. W., & Brouwers, J. R. B. J.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 2008-04
- Volume
- 63
- Issue
- 4
- Pages
- 267-279
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W2007712955
- Cited by
- 37
- References
- 12
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Aspects of Neonatal Antidepressant Withdrawal. https://app.cochat.ai/papers/10.1097/ogx.0b013e3181676be8
- The paper
- ter Horst, P. G. J., Jansman, F. G. A., van Lingen, R. A., Smit, J.-P., de Jong-van den Berg, L. T. W., & Brouwers, J. R. B. J. (2008). Pharmacological Aspects of Neonatal Antidepressant Withdrawal. Obstetrical & Gynecological Survey. https://doi.org/10.1097/ogx.0b013e3181676be8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.